(Q84552985)
Statements
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies (English)
Richard G Langley
Robert Bissonnette
Darryl Toth
Robert Matheson
Micki Hultquist